Pharmstandard pays US$590mn for Bever

26 August 2013 - Deborah Wilkes

Archived

Pharmstandard has paid US$590 million for Singapore's Bever Pharmaceutical, and moved a step closer to the planned spin-off of its branded OTC business.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: